Immunomodulatory peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-13. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
== Names == Alternative terms for low level light therapy are: LLLT, laser biostimulation, laser phototherapy, low-level laser therapy, low-power laser irradiation, low-power laser therapy, and photobiomodulation therapy. The term photobiomodulation therapy is considered the preferred term by industry professionals. However LLLT has been marketed and researched under a number of other terms, including red light therapy, low-power laser therapy (LPLT), soft laser therapy, low-intensity laser therapy, low-energy laser therapy, cold laser therapy, bio-stimulation laser therapy, photo-biotherapy, therapeutic laser, and monochromatic infrared light energy (MIRE) therapy. More specific applications sometimes have their own terms, for example when administered to acupuncture points, the procedure is called laser acupuncture. When applied to the head, LLLT may be known as transcranial photobiomodulation, transcranial near-infrared laser therapy (NILT), or transcranial low level light therapy.
Coarse-grain sugar, also known as sanding sugar, composed of reflective crystals with grain size of about 1 to 3 mm, similar to kitchen salt. Used atop baked products and candies, it will not dissolve when subjected to heat and moisture. Granulated sugar (about 0.6 mm crystals), also known as table sugar or regular sugar, is used at the table, to sprinkle on foods and to sweeten hot drinks (coffee and tea), and in home baking to add sweetness and texture to baked products (cookies and cakes) and desserts (pudding and ice cream). It is also used as a preservative to prevent micro-organisms from growing and perishable food from spoiling, as in candied fruits, jams, and marmalades. Milled sugars such as powdered sugar (icing sugar) are ground to a fine powder. They are used for dusting foods and in baking and confectionery. Screened sugars such as caster sugar are crystalline products separated according to the size of the grains. They are used for decorative table sugars, for blending in dry mixes and in baking and confectionery.
=== March === 3 March – The GMB and Unison unions have called off ambulance strikes in England scheduled for 6 and 8 March after the UK government agrees to reopen talks on pay for the 2022–23 and 2023–24 financial years. Following a trial at Luton Crown Court, four people are jailed for their part in a robbery that went wrong during which their victim, Saul Murray, was stabbed after being given the drug GHB in an attempt to knock him out. Ikem Affia is sentenced to life imprisonment for murder, with a minimum of 25 years, while the three other gang members are given lesser sentences for manslaughter. The gang were caught after one of them was captured on CCTV wearing a rare Moncler coat worth £1,000, of which only 69 had been sold in the UK. 5 March – The Unite union calls off ambulance strikes scheduled for 6 and 8 March. 8 March – The National Institute for Health and Care Excellence (NICE) approves the use of the weight loss drug semaglutide (marketed as Wegovy) by the NHS in England. 13 March – The Unite union calls off a planned strike by bus drivers at National Express West Midlands scheduled for 16 March after receiving a revised pay offer, which is to be put to members. 16 March – NHS staff in England, including nurses and ambulance staff, are offered a 5% pay rise from April along with a one-off payment of £1,655 to cover backdated pay. The offer does not include doctors, who are on a different contract.
Sources: en.wikipedia.org
=== Common names === Vernacular names used for this species include black stone flower, stone lichen, sea lichen, kalpasi, kalpas, kalpashi, and kalpash. The latter name and its variations, however, have been used as a crude drug in Indian medicines for more than one species, including Parmotrema perlatum, Parmotrema tinctorum, and Everniastrum cirrhatum. In North America, vernacular names used for the species include "powdered ruffle lichen", "powdered scatter-rug", and "queen ruffle". The species epithet perlatum refers to the pearl-like margins of the lobes, which are directly referenced in Hudson's original 1762 description of the species. He proposed the English name "pearl lichen"; this name later morphed into "pearly parmelia" in some 19th-century British accounts of lichen flora.
== Economic significance == In 2024, South Africa's logistics sector contributed R518.4 billion towards the country's GDP, a year-over-year increase of 4.3%. South Africa's logistics sector is expected to grow at a CAGR of 9.1% from 2026 to 2033. In 2025, the country accounted for 2.3% of the global logistics market. In 2026, South Africa's logistics sector was growing the fastest out of all countries in the Middle East & Africa region. Examples from Wesgro of the South African logistics sector's impact on the country's economy as a whole are in the table below.
=== Border control and fentanyl === Gallein supports border enforcement, fully funding the U.S. Border Patrol and U.S. Immigration and Customs Enforcement, completing the Mexico–United States border wall, and putting an end to the flow of illegal drugs such as fentanyl into the United States and the United States opioid epidemic.
Sources: en.wikipedia.org
== Development == Zhonghua Fu runs a clinic in Nanjing, China, affiliated with Nanjing University of Chinese Medicine. At the FSN clinic for pain medicine, FSN is used as the sole means to treat musculoskeletal disorders and some chronic benign visceral disorders. Fu originally trained as a TCM doctor, completing his masters in acupuncture. While practicing and teaching traditional acupuncture in Guangzhou, he realized that several innovations were needed to improve and accelerate the acupuncture effect. Because some techniques for painful problems in the ancient Huangdi Neijing were punctured obliquely surrounding some painful spots, Fu thought inserting horizontally was a good choice, and then FSN came into being after a number of trials. After completing his Ph.D., Fu conducted research in his lab for two years on arthritic rats. During these trials, when the needle was inserted into the local point of sensitivity, there were no profound changes in VAS and range of motion. Notable changes in VAS and range of motion were observed however when the needle was inserted parallel to the skin surface.
Type 1 is Goodpasture syndrome, an autoimmune disease also affecting the lung. In Goodpasture syndrome, IgG antibodies directed against the glomerular basement membrane trigger an inflammatory reaction, causing a nephritic syndrome and the coughing up of blood. High dose immunosuppression is required (intravenous methylprednisolone) and cyclophosphamide, plus plasmapheresis. Immunohistochemistry staining of tissue specimens shows linear IgG deposits. Type 2 is characterised by immune-complex-mediated damage, and may be associated with systemic lupus erythematosus, post-infective glomerulonephritis, IgA nephropathy, and IgA vasculitis. Type 3 rapidly progressive glomerulonephritis, also called pauciimmune type, is associated with causes of vascular inflammation including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis. No immune deposits can be seen on staining, however blood tests may be positive for the ANCA antibody. Histopathologically, the majority of glomeruli present "crescents". Formation of crescents is initiated by passage of fibrin into the Bowman space as a result of increased permeability of glomerular basement membrane. Fibrin stimulates the proliferation of endothelial cells of Bowman capsule, and an influx of monocytes. Rapid growing and fibrosis of crescents compresses the capillary loops and decreases the Bowman space, which leads to kidney failure within weeks or months.
== Adverse effects == Common side effects include headache, dizziness, feeling tired, cough, nausea, and rash. Serious side effects may include low blood pressure, liver problems, hyperkalemia, and angioedema. Use is not recommended during the entire duration of pregnancy as it may harm the baby.
After this, Agathocles of Syracuse ravaged the coast of Calabria with his fleet, took Hipponium and forced the Bruttii into unfavourable peace terms. However, they soon seized Hipponium again. After Agathloces' death in 289 BCE the Lucanians and Bruttii pushed into the territory of Thurii and ravaged it. The city sent envoys to Rome to ask for help in 285 and 282 BCE. On the second occasion, the Romans sent forces to garrison the city. This was part of the episode that sparked the Pyrrhic war. The name Italy entered common usage, defining the inhabitants of the city-states of the Mezzogiorno first as Italiotes, then Italics with the arrival of the Romans, who would later include Cisalpine Gaul.
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.